Table 1 Measures of agreement between OCR-based and POGONIS-based diagnostic groups
Malignancy type | N, POGONIS | N, OCR | Kappa (95 % CI) | Sensitivity | Specificity | PPV | NPV |
|---|---|---|---|---|---|---|---|
I. Leukemias, myeloproliferative diseases, and myelodysplastic diseases | 1305 | 1143 | 0.89 (0.88–0.91) | 0.87 | 1.00 | 0.99 | 0.94 |
II. Lymphomas and reticuloendothelial neoplasms | 585 | 554 | 0.90 (0.88–0.92) | 0.89 | 0.99 | 0.94 | 0.98 |
III. CNS and miscellaneous intracranial and intraspinal neoplasms | 790 | 757 | 0.95 (0.94–0.96) | 0.94 | 1.00 | 0.98 | 0.99 |
IV. Neuroblastoma and other peripheral nervous cell tumors | 262 | 256 | 0.97 (0.96–0.99) | 0.96 | 1.00 | 0.98 | 1.00 |
V. Retinoblastoma | 105 | 105 | 1.00 (1.00–1.00) | 1.00 | 1.00 | 1.00 | 1.00 |
VI. Renal tumors | 174 | 175 | 0.98 (0.96–0.99) | 0.98 | 1.00 | 0.98 | 1.00 |
VII. Hepatic tumors | 68 | 64 | 0.92 (0.88–0.97) | 0.90 | 1.00 | 0.95 | 1.00 |
VIII. Malignant bone tumors | 181 | 192 | 0.89 (0.86–0.92) | 0.92 | 0.99 | 0.87 | 1.00 |
IX. Soft tissue and other extraosseus sarcomas | 285 | 260 | 0.86 (0.82–0.89) | 0.82 | 0.99 | 0.91 | 0.99 |
X. Germ cell tumors, trophoblastic tumors, and neoplasms of gonads | 140 | 136 | 0.96 (0.93–0.98) | 0.94 | 1.00 | 0.97 | 1.00 |
XI. Other malignant epithelial neoplasms and malignant melanomas | 155 | 172 | 0.93 (0.90–0.96) | 0.98 | 0.99 | 0.88 | 1.00 |
XII. Other and unspecified malignant neoplasms | 23 | 259 | 0.06 (0.02–0.10) | 0.43 | 0.94 | 0.04 | 1.00 |